CU20130004A7 - Agentes terapéuticos 976 - Google Patents
Agentes terapéuticos 976Info
- Publication number
- CU20130004A7 CU20130004A7 CU2013000004A CU20130004A CU20130004A7 CU 20130004 A7 CU20130004 A7 CU 20130004A7 CU 2013000004 A CU2013000004 A CU 2013000004A CU 20130004 A CU20130004 A CU 20130004A CU 20130004 A7 CU20130004 A7 CU 20130004A7
- Authority
- CU
- Cuba
- Prior art keywords
- therapeutic agents
- azetidinyl
- compound
- melanin
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En la presente se describen compuestos azetidinílicos de fórmula I, como los descritos en la presente, composiciones farmacéuticas que comprenden un compuesto azetidinílico y un método para utilizar un compuesto azetidinílico en el tratamiento o la profilaxis de una enfermedad o afección relacionada con una hormona concentradora de melanina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36158510P | 2010-07-06 | 2010-07-06 | |
PCT/GB2011/051256 WO2012004588A2 (en) | 2010-07-06 | 2011-07-04 | Therapeutic agents 976 |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20130004A7 true CU20130004A7 (es) | 2013-05-31 |
Family
ID=44514822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2013000004A CU20130004A7 (es) | 2010-07-06 | 2013-01-04 | Agentes terapéuticos 976 |
Country Status (26)
Country | Link |
---|---|
US (1) | US8546375B2 (es) |
EP (1) | EP2590969B1 (es) |
JP (1) | JP5827683B2 (es) |
KR (1) | KR20130041177A (es) |
CN (1) | CN103209979B (es) |
AR (1) | AR082113A1 (es) |
AU (1) | AU2011275547B2 (es) |
BR (1) | BR112013000296A2 (es) |
CA (1) | CA2802832A1 (es) |
CL (1) | CL2013000027A1 (es) |
CR (1) | CR20130005A (es) |
CU (1) | CU20130004A7 (es) |
DO (1) | DOP2013000004A (es) |
EA (1) | EA201291384A1 (es) |
EC (1) | ECSP13012369A (es) |
ES (1) | ES2527466T3 (es) |
GT (1) | GT201300006A (es) |
HK (1) | HK1182712A1 (es) |
MX (1) | MX2012015102A (es) |
NI (1) | NI201200196A (es) |
PE (1) | PE20130781A1 (es) |
SA (1) | SA111320581B1 (es) |
SG (1) | SG186275A1 (es) |
TW (1) | TW201206916A (es) |
UY (1) | UY33487A (es) |
WO (1) | WO2012004588A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
CN104974106B (zh) * | 2014-04-04 | 2019-02-22 | 浙江普洛康裕制药有限公司 | 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法 |
CN108840812B (zh) * | 2018-06-29 | 2020-08-18 | 南京富润凯德生物医药有限公司 | 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4212867A (en) * | 1977-03-03 | 1980-07-15 | Philagro | 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them |
DE3039087A1 (de) | 1980-10-16 | 1982-05-19 | Hoechst Ag, 6000 Frankfurt | 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
GB2184122B (en) | 1985-12-17 | 1989-10-18 | Boots Co Plc | N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate |
JPH07502529A (ja) | 1991-12-31 | 1995-03-16 | 藤沢薬品工業株式会社 | アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体 |
JPH10507205A (ja) | 1995-08-02 | 1998-07-14 | ホータ.ウリアッヒ イ シイア.エセ.アー. | 抗真菌活性を有する新規カルボンアミド |
SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
CA2494102A1 (en) | 2002-07-30 | 2004-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
WO2004072018A1 (ja) | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
US20060293298A1 (en) | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
GB0400193D0 (en) | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
US20070185079A1 (en) | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
ATE432926T1 (de) | 2004-07-26 | 2009-06-15 | Lilly Co Eli | Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung |
JP5057982B2 (ja) | 2004-10-18 | 2012-10-24 | イーライ リリー アンド カンパニー | ヒスタミンh3受容体阻害剤、製造及び治療的使用 |
CA2589678A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Novel mch receptor antagonists |
US20080306055A1 (en) | 2004-12-21 | 2008-12-11 | Astrazeneca Ab | Heterocyclic Mchr1 Antagonists And Their Use In Therapy |
JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
BRPI0610907A2 (pt) | 2005-05-31 | 2008-12-02 | Astrazeneca Ab | composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
JP2009501217A (ja) | 2005-07-15 | 2009-01-15 | アストラゼネカ アクチボラグ | 治療薬 |
US20090076064A1 (en) | 2006-01-06 | 2009-03-19 | Astrazeneca Ab | Compounds |
AU2007275301A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
EP2121703A4 (en) | 2006-08-18 | 2011-12-28 | Astrazeneca Ab | THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS |
EP2102208B1 (en) | 2006-12-05 | 2014-04-23 | Janssen Pharmaceutica NV | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
CN101558075A (zh) * | 2006-12-14 | 2009-10-14 | 伊莱利利公司 | 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 |
EP2148931A2 (en) | 2007-04-17 | 2010-02-03 | Vertex Pharmaceuticals Incorporated | Drug discovery methods for aurora kinase inhibitors |
CA2694499A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
KR101194467B1 (ko) | 2007-08-22 | 2012-10-24 | 에프. 호프만-라 로슈 아게 | Nk3 수용체 길항제로서의 피롤리딘 아릴-에터 |
RU2477720C2 (ru) * | 2007-10-17 | 2013-03-20 | Санофи-Авентис | Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях |
US8124636B2 (en) | 2008-04-30 | 2012-02-28 | Hoffmann-La Roche Inc. | Imidazolidinone derivatives as 11B-HSD1 inhibitors |
WO2009135842A1 (en) * | 2008-05-08 | 2009-11-12 | Evotec Neurosciences Gmbh | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
US9006232B2 (en) | 2009-08-13 | 2015-04-14 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives |
WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
-
2011
- 2011-07-04 MX MX2012015102A patent/MX2012015102A/es active IP Right Grant
- 2011-07-04 SG SG2012090882A patent/SG186275A1/en unknown
- 2011-07-04 PE PE2013000016A patent/PE20130781A1/es not_active Application Discontinuation
- 2011-07-04 EA EA201291384A patent/EA201291384A1/ru unknown
- 2011-07-04 JP JP2013517542A patent/JP5827683B2/ja not_active Expired - Fee Related
- 2011-07-04 CA CA2802832A patent/CA2802832A1/en not_active Abandoned
- 2011-07-04 KR KR1020137003150A patent/KR20130041177A/ko not_active Application Discontinuation
- 2011-07-04 ES ES11729458.7T patent/ES2527466T3/es active Active
- 2011-07-04 AU AU2011275547A patent/AU2011275547B2/en not_active Ceased
- 2011-07-04 CN CN201180042363.6A patent/CN103209979B/zh not_active Expired - Fee Related
- 2011-07-04 WO PCT/GB2011/051256 patent/WO2012004588A2/en active Application Filing
- 2011-07-04 BR BR112013000296A patent/BR112013000296A2/pt not_active IP Right Cessation
- 2011-07-04 EP EP11729458.7A patent/EP2590969B1/en active Active
- 2011-07-04 SA SA111320581A patent/SA111320581B1/ar unknown
- 2011-07-05 AR ARP110102401A patent/AR082113A1/es not_active Application Discontinuation
- 2011-07-05 US US13/176,554 patent/US8546375B2/en not_active Expired - Fee Related
- 2011-07-05 TW TW100123724A patent/TW201206916A/zh unknown
- 2011-07-06 UY UY0001033487A patent/UY33487A/es not_active Application Discontinuation
-
2012
- 2012-12-28 NI NI201200196A patent/NI201200196A/es unknown
-
2013
- 2013-01-03 CL CL2013000027A patent/CL2013000027A1/es unknown
- 2013-01-04 DO DO2013000004A patent/DOP2013000004A/es unknown
- 2013-01-04 CU CU2013000004A patent/CU20130004A7/es unknown
- 2013-01-04 GT GT201300006A patent/GT201300006A/es unknown
- 2013-01-04 EC ECSP13012369 patent/ECSP13012369A/es unknown
- 2013-01-07 CR CR20130005A patent/CR20130005A/es unknown
- 2013-08-30 HK HK13110163.5A patent/HK1182712A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CL2013000027A1 (es) | 2013-03-08 |
US20120010189A1 (en) | 2012-01-12 |
CR20130005A (es) | 2013-04-17 |
CN103209979B (zh) | 2016-02-10 |
PE20130781A1 (es) | 2013-07-20 |
TW201206916A (en) | 2012-02-16 |
CA2802832A1 (en) | 2012-01-12 |
SA111320581B1 (ar) | 2014-06-17 |
AU2011275547B2 (en) | 2015-10-29 |
NI201200196A (es) | 2013-10-16 |
WO2012004588A3 (en) | 2012-08-09 |
US8546375B2 (en) | 2013-10-01 |
MX2012015102A (es) | 2013-05-01 |
JP2013535413A (ja) | 2013-09-12 |
KR20130041177A (ko) | 2013-04-24 |
ES2527466T3 (es) | 2015-01-26 |
EA201291384A1 (ru) | 2013-07-30 |
ECSP13012369A (es) | 2013-01-31 |
UY33487A (es) | 2012-02-29 |
AR082113A1 (es) | 2012-11-14 |
EP2590969A2 (en) | 2013-05-15 |
DOP2013000004A (es) | 2013-04-30 |
GT201300006A (es) | 2014-11-06 |
WO2012004588A2 (en) | 2012-01-12 |
AU2011275547A1 (en) | 2013-02-07 |
HK1182712A1 (en) | 2013-12-06 |
JP5827683B2 (ja) | 2015-12-02 |
CN103209979A (zh) | 2013-07-17 |
BR112013000296A2 (pt) | 2019-09-24 |
EP2590969B1 (en) | 2014-10-15 |
SG186275A1 (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
DOP2013000104A (es) | Antagonistas de mdm2 de espiro-oxindol | |
UY33029A (es) | Antagonistas de espiro-oxindol de mdm2 | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2014000428A1 (es) | Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica. | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
IN2015DN01329A (es) | ||
CU20130004A7 (es) | Agentes terapéuticos 976 | |
AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? | |
CR20160116A (es) | Método para tratar onicomicosis con hidroxipropil quitasano | |
EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
RS54022B1 (en) | COMPOSITION OF VIRUS INHIBITOR FOR INVIVE THERAPEUTIC USE | |
AR063530A1 (es) | Procedimiento de utilizacion de enoxaparina sodica para la preparacion de un medicamento | |
DOP2014000103A (es) | Composición con un inhibidor de la bomba de protones y un antagonista h2 |